Indication
coronary artery disease
6 clinical trials
8 products
Product
PET MPIProduct
SPECT MPIProduct
XTR004Clinical trial
Evaluation of XTR004 as a Novel 18F-labeled PET Myocardial Perfusion Imaging (MPI) Tracer in Diagnosis of Known or Suspected CAD Compared With Invasive Coronary Angiography, Fractional Flow Reserve, Index of Microcirculatory ResistanceStatus: Completed, Estimated PCD: 2023-05-09
Clinical trial
A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery DiseaseStatus: Completed, Estimated PCD: 2022-05-05
Clinical trial
A Descriptive, Comparative, Randomized, Crossover Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion Imaging Quality Using High Performance Liquid Chromatography (HPLC) and Solid Phase Extraction (SPE) Manufacturing ProcessesStatus: Completed, Estimated PCD: 2022-05-26
Product
FlurpiridazClinical trial
Effectiveness and Safety of Low Dose Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic RiskStatus: Completed, Estimated PCD: 2023-09-13
Product
RivaroxabanClinical trial
Essential Pro Post-Market Clinical Follow-up StudyStatus: Recruiting, Estimated PCD: 2025-02-02
Product
Essential proClinical trial
Impact of Chronic Kidney Disease (CKD) on Pharmacodynamic Profiles of the P2Y12 Receptor Inhibitor Clopidogrel in the Setting of Type 2 Diabetes Mellitus (T2DM) and Coronary Artery Disease (CAD)Status: Completed, Estimated PCD: 2022-05-23
Product
Clopidogrel